10/519793

7712 Rec'd PCT/PTO 2 3 DEC 2004

Application Data Sheet

Application Information

Application Type::

Regular

Subject Matter::

Utility

Suggested Classification::

N/A.

Suggested Group Art Unit::

N/A

Title::

Methods For Treating Alzheimer's Disease Using

Hydroxyethylene Compounds Containing A Heteroyclic

Amide Bond Isostere

Attorney Docket Number::

02-456-A1

Request for Early Publication?::

No

Request for Non-Publication?::

No

Suggested Drawing Figure::

N/A

Total Drawing Sheets::

N/A

Small Entity::

No

Petition Included?::

No

Applicant Information

Applicant Authority type::

Inventor

Primary Citizenship Country::

United States of America

Status::

Full Capacity

Given Name::

Varghesė

Family Name::

John

City of Residence::

San Francisco

State of Residence::

California

Country of Residence::

United States of America

Street of mailing address::

1722 18th Avenue

City of mailing address::

San Francisco

State of mailing address::

California

Zip Code of mailing address::

94112

Correspondence Information

Correspondence Customer Number::

020306

Name Line One::

Steven J. Sarussi

Name Line Two::

McDonnell Boehnen Hulbert & Berghoff

Street of Mailing Address ::

32nd Floor

Street of Mailing Address::

300 S. Wacker Drive

City of Mailing Address::

Chicago

State or Providence of Mailing Address:: IL

Country of Mailing Address::

USA

Postal or Zip Code of Mailing Address:: 60606

Phone Number::

(312) 913-0001

Fax Number::

(312) 913-0002

E-Mail Address::

docketing@mbhb.com

Representative Information

	Representative Customer Number::	020306
--	----------------------------------	--------

Priority Information

Application::	Continuity Type:	Parent Application::	Parent Filing Date::
This Application	National Phase, claims the benefit of 35 USC 371 of	PCT/US03/20383	June 27, 2003
	1. 22 22 31 7 31		

Domestic Priority Information

Country::	Application Number::	Filing Date::	Priority Claimed::
United States	60/392,129	June 27, 2002	Yes

Assignee Information

Assignee Name:: 1) Elan Pharmaceuticals, Inc.